CX-2043, an EpCAM-targeting probody drug conjugate, demonstrates anti-tumor activity with a favorable safety profile in preclinical models. (October 2020) - Liu, B.; Shen, J.; Yu, W.; Jing, C.; Saha, S.; Rangan, V.; Richardson, J.; Liu, Y.; Boule, S.; Lucas, J.; Ab, O.; Hicks, S.; et al.